Clinical Trials Logo

Clinical Trial Summary

PEMF (Pulsed Electro Magnetic Fields) therapy has been used to stimulate bone repair in non-union since the 1970s. This is an accepted use, which has been approved by the Food and Drug Administration in the US. The mode of action of PEMF is based on creating small electrical fields in tissue and thereby promoting healing. Besides it has been shown that PEMF enhance regeneration of nerve fibers exposed to a lesion For treatment of depression the PEMF equipment, which are provided by the company Re5 A/S, consists of a 220 V impulse generator that creates electrical impulses and an applicator which consists of an electrical cable connected to a helmet on which there are 7 electrical coils on the inside. In comparison with the rTMS (Transcranial Magnetic Stimulation) equipment, which uses stimuli approaching neuronal firing level, the PEMF fields in human is very much lower.


Clinical Trial Description

Applied to cells PEMF have a stimulatory effect on intracellular tyrosine kinase activity, especially the Src family. The Src family upregulate NMDAR (N-methyl-D-aspartate) subtype of glutamate receptor thereby gating the production of NMDAR-dependent synaptic potentiation that are vital for processes that underlie physiological and pathological plasticity in the brain. Dysregulation of fibroblast growth factor receptors in frontal cortical regions of the brain seem to be associated with depression. The fibroblast growth factors are highly dependent on the activity of the Src family.

For treatment of depression the PEMF equipment, which are provided by the company Re5 A/S, consists of a 220 V impulse generator that creates electrical impulses and an applicator which consists of an electrical cable connected to a helmet on which there are 7 electrical coils on the inside. In comparison with the rTMS equipment, which uses stimuli approaching neuronal firing level, the PEMF fields in human are very much lower.

PEMF treatment involves placing the treatment helmet on the head and connecting it to a power source (220 V), which leads to induction of a pulsating magnetic field. The treatment was given for 30 min once or twice daily for 8 weeks. Participants are awake during these treatments and sit in a chair where they can read or eat. Pilot data demonstrates that the treatment can give mild transient nausea. No other side effects have been observed. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03556735
Study type Interventional
Source University of Southern Denmark
Contact
Status Completed
Phase N/A
Start date September 2016
Completion date December 2017

See also
  Status Clinical Trial Phase
Active, not recruiting NCT05114824 - Acceptability and Feasibility of an 8-week Online Mindfulness-Based Cognitive Therapy Program Among Undergraduate Students N/A
Not yet recruiting NCT05958940 - BioClock: Bright Light Therapy for Depressive Disorders N/A
Completed NCT04916548 - Repeated Neurocognitive Measurements in Depressed Patients Phase 1/Phase 2
Recruiting NCT05767073 - LIVES: Personalized Lifestyle Intervention for Patients With Depression N/A
Recruiting NCT06094907 - Safety, Tolerability and Antidepressant Effects of DMT in Patients With Depression Phase 2
Completed NCT04121091 - Pramipexole to Target "Anhedonic Depression" Phase 2
Not yet recruiting NCT06092411 - Effects of CBT and BLT in Youth With Unipolar Depression and Evening Chronotype N/A
Enrolling by invitation NCT03847688 - Machine Learning to Predict Clinical Response to TMS
Completed NCT02945735 - Gaze Contingent Feedback in Major Depressive Disorder (MDD) N/A
Recruiting NCT06139159 - CRISOL Mente: A Multilevel Community Intervention to Reduce Mental Health Disparities Among Latinos N/A
Recruiting NCT05011864 - Integrated Tele-Behavioral Activation and Fall Prevention for Low-income Homebound Seniors With Depression N/A
Terminated NCT03537547 - Combinatorial Pharmacogenomics Testing in Treatment-Naïve Major Depressive Disorder Phase 4
Completed NCT03515733 - PF-04995274 and Emotional Processing in Treatment Resistant Depression Phase 1
Not yet recruiting NCT05991232 - Repeated Neurocognitive Measurements in Depressed Patients Phase 1/Phase 2
Completed NCT03516604 - PF-04995274 and Emotional Processing in Un-medicated Depression Phase 1
Completed NCT03538275 - Chronobiology and Depression: Circadian Analytics as a Biomarker for Depressive Subtypes
Active, not recruiting NCT03096886 - Novel Neural Circuit Biomarkers of Major Depression Response to CCBT N/A
Completed NCT01874951 - Low-Dose Naltrexone for Depression Relapse and Recurrence Phase 2
Completed NCT03906175 - Whole-body Hyperthermia for Mild to Moderate Depressive Disorder N/A
Active, not recruiting NCT05930912 - Psychiatric Orders in Psychoanalytic Treatment of ASD